Ashton William 4

What Happened

• Ashton William, a director of Medicus Pharma Ltd. (MDCX), received an award/acquisition of 25,000 derivative shares on 2026-03-30. The Form 4 reports an acquisition at $0.00 per share (total cash paid $0), indicating a grant or similar equity award rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-30
• Filing date (Form 4): 2026-04-01; Accession: 0000950142-26-001021
• Security: 25,000 shares (classified as a derivative award) at $0.00 per share
• Total cash paid reported: $0
• Shares owned after transaction: not specified in the provided excerpt
• No 10b5-1, tax-withholding, or late-filing flag noted in the provided data

Context

• The filing classifies this as a derivative award (transaction code A), which typically means rights to receive common stock—examples include restricted stock grants or restricted stock units (RSUs). Such awards are often part of compensation or retention programs and are different from open-market purchases that signal a direct personal investment.
• Awards at $0 reported in the Form 4 reflect the grant itself; vesting schedules, taxation, and any future sales, if and when they occur, can affect the economic impact and insider incentive.